-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14

Benzinga·11/10/2026 13:28:02
Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $9 to $14.